Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Lixisenatide Success
Next possible GLP-1 diabetes drug from Sanofi-Aventis (lixisenatide) has success in a late stage trial, reducing A1c and body weight without increasing risk of hypoglycemi
BYDUREON™ recommended for approval in Europe.
BYDUREON would be first once-weekly treatment for adults with Type 2 diabetes.